CSIMarket
 



Catalyst Pharmaceuticals Inc   (CPRX)
Other Ticker:  
 
 



 

What are Catalyst Pharmaceuticals Inc's Business Segments?



Catalyst Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and commercialization of prescription drugs for rare and debilitating neurological diseases. Catalyst's product portfolio consists of two segments: Firdapse and CPP-115.

Firdapse (Amifampridine Phosphate)

Firdapse is a medication that is designed to improve muscle function in individuals who suffer from Lambert-Eaton Myasthenic Syndrome (LEMS). LEMS is a rare neuromuscular disease that affects the connection between nerve and muscle cells causing reduced strength and fatigue. Firdapse works by increasing the release of a chemical called acetylcholine which aids in the transmission of signals to the muscles. Catalyst Pharmaceuticals Inc holds the exclusive rights to Firdapse in North America, Europe, and Japan.

CPP-115

CPP-115 is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor that is currently in the preclinical stage of development. GABA is a neurotransmitter that helps to reduce the overactivity of neurons in the brain. In a preclinical study, CPP-115 demonstrated the potential to reduce seizure activity in certain types of epilepsy.

In addition to its product portfolio, Catalyst Pharmaceuticals Inc offers a range of services that aim to support patients, healthcare providers, and caregivers. These services include:

- Patient Assistance Program: This program assists eligible patients in accessing Firdapse at no cost or reduced cost.
- Reimbursement Support: Catalyst's reimbursement support team helps patients to navigate insurance claims and maintains communication with insurance providers and healthcare providers.
- Disease Education and Awareness: Catalyst provides educational resources and materials to patients, healthcare providers, and caregivers to increase awareness and understanding of rare neurological diseases like LEMS.
- Clinical Trials: Catalyst is committed to conducting clinical trials that are focused on finding new treatments for rare neurological diseases. Through these trials, the company aims to contribute to the advancement of the medical community and improve patient outcomes.

In conclusion, Catalyst Pharmaceuticals Inc focuses on providing innovative treatments for rare and debilitating neurological diseases. Its product portfolio consists of Firdapse, an FDA-approved medication for LEMS, and CPP-115, a preclinical-stage drug for certain types of epilepsy. The company aims to support patients, healthcare providers, and caregivers through its patient assistance program, reimbursement support, disease education and awareness, and clinical trials.
   

Catalyst Pharmaceuticals Inc Tax Rate Companies within the Major Pharmaceutical Preparations Industry


Business Segments Q4
Revenues
(in millions $)
Q4
Income
(in millions $)
(Dec 31 2023)
%
(Profit Margin)
Total 110.57 34.84 31.51 %

Growth rates by Segment Q4
Y/Y Revenue
%
(Dec 31 2023)
Q/Q Revenue
%
Q4
Y/Y Income
%
(Dec 31 2023)
Q/Q Income
%
Total 81.98 % 7.67 % 36.8 % -

To get more information on Catalyst Pharmaceuticals Inc's Total segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com